{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:01:50Z","timestamp":1762077710299,"version":"build-2065373602"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011848","name":"Novo Nordisk Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011848","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010875","name":"Amgen Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010875","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013739","name":"Pfizer Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013739","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008207","name":"AstraZeneca Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008207","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014554","name":"Janssen Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014554","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.ahj.2019.09.013","type":"journal-article","created":{"date-parts":[[2019,10,20]],"date-time":"2019-10-20T17:06:55Z","timestamp":1571591215000},"page":"92-99","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Associations between \u03b2-blocker therapy and cardiovascular outcomes in patients with diabetes and established cardiovascular disease"],"prefix":"10.1016","volume":"218","author":[{"given":"Jay S.","family":"Shavadia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinggan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer B.","family":"Green","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul W.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia M.","family":"Westerhout","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darren K.","family":"McGuire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan H.","family":"Cornel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rury R.","family":"Holman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric D.","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2019.09.013_bb0005","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1056\/NEJM198104023041401","article-title":"Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction","volume":"304","author":"Norwegian Multicenter Study Group","year":"1981","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2019.09.013_bb0010","first-page":"1707","article-title":"Mortality results","volume":"247","author":"A randomized trial of propranolol in patients with acute myocardial infarction. I","year":"1982","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2019.09.013_bb0015","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0140-6736(00)04560-8","article-title":"Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial","volume":"357","author":"Dargie","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2019.09.013_bb0020","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1136\/bmj.318.7200.1730","article-title":"Harrison J. \u03b2 Blockade after myocardial infarction: systematic review and meta regression analysis","volume":"318","author":"Freemantle","year":"1999","journal-title":"BMJ"},{"key":"10.1016\/j.ahj.2019.09.013_bb0025","doi-asserted-by":"crossref","unstructured":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9\u201313.","DOI":"10.1016\/S0140-6736(98)11181-9"},{"key":"10.1016\/j.ahj.2019.09.013_bb0030","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","article-title":"Metoprolol CR\/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)","volume":"353","author":"Effect of metoprolol CR\/XL in chronic heart failure","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2019.09.013_bb0035","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1161\/01.CIR.98.12.1184","article-title":"Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials","volume":"98","author":"Lechat","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2019.09.013_bb0040","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.amjcard.2018.01.015","volume":"121","author":"Spitaleri","year":"2018","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2019.09.013_bb0045","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jcin.2013.12.206","article-title":"Association of beta-blocker therapy at discharge with clinical outcomes in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention","volume":"7","author":"Yang","year":"2014","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2019.09.013_bb0050","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1001\/jama.2012.12559","article-title":"\u03b2-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease","volume":"308","author":"Bangalore","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2019.09.013_bb0055","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1016\/j.jacc.2017.03.578","article-title":"\u03b2-Blockers and mortality after acute myocardial infarction in patients without heart failure or ventricular dysfunction","volume":"69","author":"Dondo","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2019.09.013_bb0060","doi-asserted-by":"crossref","unstructured":"Puymirat E, Riant E, Aissoui N, et al. \u03b2 blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study. BMJ 2016;354:i4801.","DOI":"10.1136\/bmj.i4801"},{"key":"10.1016\/j.ahj.2019.09.013_bb0065","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1161\/HYPERTENSIONAHA.117.09259","article-title":"Risk of cardiovascular events in patients with diabetes mellitus on beta-blockers","volume":"70","author":"Tsujimoto","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.ahj.2019.09.013_bb0070","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.jacc.2017.07.783","article-title":"Adherence tradeoff to multiple preventive therapies and all-cause mortality after acute myocardial infarction","volume":"70","author":"Korhonen","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2019.09.013_bb0075","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1161\/CIRCULATIONAHA.117.029190","volume":"136","author":"Kosiborod","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2019.09.013_bb0080","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S2213-8587(17)30412-6","article-title":"Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"Bethel","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ahj.2019.09.013_bb0085","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2019.09.013_bb0090","doi-asserted-by":"crossref","unstructured":"Green JB, Bethel MA, Paul SK, et al. Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. Am Heart J 2013;166:983\u20139.e7.","DOI":"10.1016\/j.ahj.2013.09.003"},{"key":"10.1016\/j.ahj.2019.09.013_bb0095","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2337\/dc17-1778","article-title":"Increased risk of severe hypoglycemic events before and after cardiovascular outcomes in TECOS suggests an at-risk type 2 diabetes frail patient phenotype","volume":"41","author":"Standl","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ahj.2019.09.013_bb0100","series-title":"1997 Proceedings of the Section on Bayesian Statistical Science. Alexandria, VA: American Statistical Association","first-page":"1","article-title":"Marginal structural models","author":"Robins","year":"1998"},{"key":"10.1016\/j.ahj.2019.09.013_bb0105","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1161\/CIR.0b013e318235eb4d","article-title":"AHA\/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation","volume":"124","author":"Smith","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2019.09.013_bb0110","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrcardio.2012.159","article-title":"Coronary artery disease. Are \u03b2-blockers truly helpful in patients with CAD?","volume":"10","author":"Danchin","year":"2013","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.ahj.2019.09.013_bb0115","first-page":"2721","article-title":"The swing of beta-blockers: time for a system reboot","volume":"69","author":"Ibanez","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2019.09.013_bb0120","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000001629","article-title":"Effectiveness of prior use of beta-blockers for preventing adverse influences of severe hypoglycemia in patients with diabetes: an observational study","volume":"94","author":"Tsujimoto","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ahj.2019.09.013_bb0125","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Dahlof","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2019.09.013_bb0130","first-page":"149","article-title":"Different long-term metabolic effects of enalapril and atenolol in patients with mild hypertension","volume":"9","author":"Aberg","year":"1995","journal-title":"EGTA Group J Hum Hypertens"},{"key":"10.1016\/j.ahj.2019.09.013_bb0135","first-page":"1008","article-title":"Veterans Administration Cooperative Study Group on Antihypertensive Agents","volume":"7","author":"Propranolol or hydrochlorothiazide alone for the initial treatment of hypertension. IV. Effect on plasma glucose and glucose tolerance","year":"1985","journal-title":"Hypertension"},{"key":"10.1016\/j.ahj.2019.09.013_bb0140","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/qjmed\/hcl059","article-title":"Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control","volume":"99","author":"Sarafidis","year":"2006","journal-title":"QJM"},{"key":"10.1016\/j.ahj.2019.09.013_bb0145","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1001\/jama.290.21.2805","article-title":"Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial","volume":"290","author":"Pepine","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2019.09.013_bb0150","doi-asserted-by":"crossref","first-page":"982","DOI":"10.2337\/dc07-1768","article-title":"Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial--Blood Pressure Lowering Arm and the relative influence of antihypertensive medication","volume":"31","author":"Gupta","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ahj.2019.09.013_bb0155","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S0140-6736(02)08090-X","article-title":"Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Lindholm","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2019.09.013_bb0160","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","volume":"366","author":"Dahlof","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2019.09.013_bb0165","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/S0140-6736(04)17355-8","article-title":"Atenolol in hypertension: is it a wise choice?","volume":"364","author":"Carlberg","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2019.09.013_bb0170","article-title":"Beta-blockers for hypertension","volume":"11","author":"Wiysonge","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ahj.2019.09.013_bb0175","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(05)67573-3","article-title":"Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis","volume":"366","author":"Lindholm","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2019.09.013_bb0180","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/S0140-6736(68)90272-9","article-title":"Propranolol and hypoglycaemia","volume":"1","author":"Reveno","year":"1968","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2019.09.013_bb0185","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2337\/dc11-0996","article-title":"The impact of frequent and unrecognized hypoglycemia on mortality in the ACCORD study","volume":"35","author":"Seaquist","year":"2012","journal-title":"Diabetes Care"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870319302716?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870319302716?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T09:57:02Z","timestamp":1762077422000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870319302716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":37,"alternative-id":["S0002870319302716"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2019.09.013","relation":{},"ISSN":["0002-8703"],"issn-type":[{"type":"print","value":"0002-8703"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Associations between \u03b2-blocker therapy and cardiovascular outcomes in patients with diabetes and established cardiovascular disease","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2019.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}